# Allorion Therapeutics

> Allorion Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 by Qiang Ding
> and Fang Li, with operations in Natick, Massachusetts and Guangzhou, China. It discovers and
> develops novel small-molecule therapies for cancer and autoimmune disease, focusing on
> mutant-selective and isoform-specific inhibitors intended to improve efficacy and forestall
> resistance. Allorion does not run a developer program and publishes no API.

<!--
generated: 2026-08-06
method: generated
source: apis.yml + live probes of alloriontx.com on 2026-08-06
note: Generated by the API Evangelist enrichment pipeline. Allorion Therapeutics does not publish an
      llms.txt of its own — https://alloriontx.com/llms.txt is answered by the site's SiteGround
      CAPTCHA interstitial and no llms.txt document exists behind it.
-->

## About

Allorion pairs medicinal chemistry with internal data and high-throughput screening platforms to
pursue well-validated oncology and immunology targets with mutant-selective and isoform-specific
molecules. The company has raised approximately $100M from investors including Qiming Venture
Partners and INCE Capital, and has partnered its programs with larger developers.

## Pipeline

- **ARTS-011** — a TYK2 inhibitor with selectivity against the other JAK-family kinases; has
  completed a Phase 1 trial in healthy volunteers in China.
- **ARTS-021** — a CDK2 inhibitor shown to selectively inhibit growth of tumors carrying CCNE1
  amplification.
- **ARTS-023 / AVZO-023** — partnered with Avenzo Therapeutics and in Phase 1 evaluation in the
  United States for advanced solid tumors.
- **Allosteric EGFR L858R inhibitor** — subject of an exclusive option and global license agreement
  with AstraZeneca, aimed at advanced EGFR-mutant non-small-cell lung cancer.

## Site

- [Home](https://alloriontx.com/)
- [Overview](https://alloriontx.com/overview/)
- [Our Team](https://alloriontx.com/our-team/)
- [Pipeline](https://alloriontx.com/pipeline/)
- [Presentations](https://alloriontx.com/presentations/)
- [News](https://alloriontx.com/news/)
- [Careers](https://alloriontx.com/careers/)
- [Contact](https://alloriontx.com/contact/)
- [LinkedIn](https://www.linkedin.com/company/alloriontx/)
- [Twitter/X](https://twitter.com/AllorionT)

## APIs

Allorion Therapeutics publishes no API. As of 2026-08-06 there is no developer portal, no API
documentation, no SDK, no OpenAPI/Swagger/AsyncAPI/GraphQL contract, no MCP server and no A2A agent
card. No `api.`, `developer.`, `docs.`, `dev.`, `portal.` or `app.` host resolves for
alloriontx.com, and no `allorion`, `alloriontx` or `allorion-therapeutics` GitHub organisation
exists. The "data and screening platforms" the company markets are internal drug-discovery
capabilities, not a product with a public interface.

No first-party client library exists in any public package registry. The GitHub user `Allorion` and
the npm packages `allorion-exporting-html-to-xlsx` / `allorion-exporting-html-to-docx` belong to an
unrelated party named Allori and must not be attributed to this company.

Automated requests to alloriontx.com are answered by a SiteGround CAPTCHA interstitial (HTTP 202
with a meta-refresh to `/.well-known/sgcaptcha/`), so the site is effectively closed to unattended
agents even though its robots.txt disallows nothing.

## API Evangelist profile

- [apis.yml](https://raw.githubusercontent.com/api-evangelist/allorion-therapeutics/refs/heads/main/apis.yml)
- [Well-known / discovery probe results](https://raw.githubusercontent.com/api-evangelist/allorion-therapeutics/refs/heads/main/well-known/allorion-therapeutics-well-known.yml)
- [Domain security probe](https://raw.githubusercontent.com/api-evangelist/allorion-therapeutics/refs/heads/main/security/allorion-therapeutics-domain-security.yml)